异甘草酸镁注射液联合恩替卡韦对慢性乙型肝炎患者肝功能和sICAM-1、sFas水平的影响

Effect of Magnesium Isoglycyrrhizinate Injection combined with entecavir in treatment of chronic hepatitis B and its effect on levels of sICAM-1 and sFAS

目的探讨异甘草酸镁注射液联合恩替卡韦治疗慢性乙型肝炎的疗效及其对可溶性细胞间黏附分子-1(sICAM-1)和Fas受体(sFas)水平的影响。方法选择2017年10月—2020年9月在聊城市第二人民医院治疗的慢性乙型肝炎患者82例为研究对象,根据治疗方法将患者分为对照组和观察组,每组各41例。对照组口服恩替卡韦分散片,0.5 mg/次,1次/d。观察组在对照组基础上静脉滴注异甘草酸镁注射液,0.1 g混合250 mL生理盐水中,1次/d,连续治疗3个月。比较两组肝功能、sICAM-1、sFas水平、不良反应发生率、乙肝病毒的脱氧核糖核酸(HBV-DNA)、乙型肝炎E抗原(HBeAg)转移率。结果治疗后,两组丙氨酸氨基转移酶(ALT)、天冬氨酸转氨酶(AST)、总胆红素(TbiL)和甲胎蛋白(AFP)水平均显著降低(P<0.05);且观察组肝功能水平显著低于对照组(P<0.05)。治疗后,两组sICAM-1、sFas水平均显著低于用药前(P<0.05);观察组治疗后sICAM-1、sFas水平显著低于对照组(P<0.05)。两组用药期间不良反应发生率无统计学意义;观察组治疗后HBV-DNA、HBeAg转阴率均高于对照组(P<0.05)。结论异甘草酸镁注射液联合恩替卡韦能改善慢性乙型肝炎患者肝功能水平,能降低SICAM-1、SFas水平,未增加不良反应发生率,可提高患者转阴率,值得推广应用。

Objective To investigate the efficacy of Magnesium Isoglycyrrhizinate Injection combined with entecavir in treatment of chronic hepatitis B,and its effect on sICAM-1 and sFas levels.Methods A total of 82 patients with chronic hepatitis B from October 2017 to September 2020 in the Liaocheng Second People's Hospital were selected as the research subjects.According to the treatment methods,the patients were divided into control group and observation group,with 41 patients in each group.Patients in the control group were po administered with Entecavir Dispersible Tablets,0.5 mg/time,once daily.Patients in the observation group were iv administered with Magnesium Isoglycyrrhizinate Injection on the basis of control group,0.1 g mixed with 250 mL normal saline,once daily.The two groups were treated for 3 months.The liver function level,SICAM-1,SFAS level,incidence of adverse reactions,HBV DNA and HBeAg metastasis rate were compared between two groups.Results After treatment,the levels of ALT,AST,TBIL,and AFP in two groups were significantly decreased(P<0.05).The level of liver function in observation group was significantly lower than that in control group(P<0.05).After treatment,the levels of sICAM-1 and sFAS in two groups were significantly lower than before(P<0.05).The levels of sICAM-1 and sFAS in observation group were significantly lower than those in control group after treatment(P<0.05).There was no statistical significance in the incidence of adverse reactions between two groups.The negative conversion rate of HBV-DNA and HBeAg in the observation group was higher than that in the control group(P<0.05).Conclusion Enticavir combined with Magnesium Isoglycyrrhizinate Injection can improve the level of liver function in patients with chronic hepatitis B,reduce the levels of sICAM-1 and sFAS,do not increase the incidence of adverse reactions,can improve the negative rate of patients,worthy of application.